Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Zilovertamab is a Humanised Monoclonal ROR1 Antibody - Network of ...
Zilovertamab Vedotin – Application in Therapy and Current Clinical Research
U.S. FDA approves Phase 3 Study Design for Zilovertamab in the ...
Zilovertamab vedotin (VLS-101) 靶向ROR1的抗体药物偶联物（ADC） - 哔哩哔哩
(PDF) Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid ...
A phase 1b study of zilovertamab in combination with paclitaxel for ...
Study of Zilovertamab Vedotin and Drug Combination for Untreated ...
Study on the Safety and Effectiveness of Zilovertamab Vedotin for ...
Zilovertamab inhibits Wnt5a-induced venetoclax-resistance and ...
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers ...
(PDF) A phase 1b study of zilovertamab in combination with paclitaxel ...
Zilovertamab Vedotin + R-CHP for Diffuse Large B-Cell Lymphoma Clinical ...
The effect of zilovertamab ("zilo") +/− Paclitaxel, Cisplatin, Olaparib ...
Zilovertamab (UC-961) | ROR1 Inhibitor | MedChemExpress
Zilovertamab vedotin(Zilovertamab vedotin) - 药物靶点：ROR1 x Tubulin_在研适应症 ...
Zilovertamab vedotin (VLS-101) | Antibody-Drug Conjugate | MedChemExpress
Zilovertamab Vedotin: Merck's Next-Gen ADC Poised to Dominate Relapsed ...
Zilovertamab Vedotin Monotherapy for Patients with Relapsed or ...
Phase 3 Study to Evaluate Ibrutinib Plus Zilovertamab for R/R MCL Treatment
Phase 3 waveLINE-010 Study Starts for Zilovertamab Vedotin in DLBCL
FDA Okays Phase 3 Study of Zilovertamab in R/R Mantle Cell Lymphoma
Merck’s Investigational Zilovertamab Vedotin Showed Promising Antitumor ...
Combination Zilovertamab Vedotin and R-GemOx is Safe, Effective in R/R ...
A Study of Zilovertamab Vedotin as Monotherapy and in Combination in ...
Phase 3 waveLINE-010 Study Starts for Zilovertamab Vedotin in DLBCL ...
Zilovertamab Vedotin in Mantle Cell Lymphoma: Promising Results from ...
Buy research grade Zilovertamab biosimilar ，anti-UC-961, cirmtuzumab ...
(PDF) P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140 ...
Merck Launches Phase III Trial Evaluating Zilovertamab Vedotin in ...
The addition of zilovertamab vedotin to standard R-GemOx generated ...
Buy Zilovertamab Biosimilar - Anti-ROR1 mAb - Research Grade Online
Table 1 from Zilovertamab Vedotin Targeting of ROR1 as Therapy for ...
Zilovertamab Vedotin与Polivy I临床数据对比（非头对头） - 2025年03月 - 行业研究数据 - 小牛行研
MSD Presents Zilovertamab Vedotin Results at ASCO Annual Meeting ...
Zilovertamab Vedotin Plus Chemo Combo Shows Responses in R/R DLBCL
anti-Zilovertamab antibody | Human anti-ROR1 Zilovertamab Monoclonal ...
Zilovertamab Vedotin: Merck's Oncology Breakthrough in DLBCL – A ...
Trial Work Progressing and Encouraging for Zilovertamab Vedotin Combo ...
Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL
Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic ...
Zilovertamab vedotin: Uses, Interactions, Mechanism of Action | DrugBank
Study Comparing Zilovertamab Vedotin with Drug Combination for ...
Zilovertamab Vedotin Produces Activity in Heavily Pretreated R/R Mantle ...
The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the ...
Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large ...
Merck Highlights the P-II (WaveLINE-007) Study Data of Zilovertamab ...
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse ...
VIDEO: Zilovertamab vedotin regimen shows promise in diffuse large B ...
Zilovertamab Vedotin Shows Clinical Activity in Relapsed/Refractory ...
Merck Zilovertamab Shows 100% Remission in DLBCL Trial
Merck's Zilovertamab Vedotin Shows 100% CR Rate in Phase II Study for ...
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin ...
Tolerability of Zilovertamab and Ibrutinib in Phase 1/2 Trial of MCL ...
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult ...
Merck's Zilovertamab Vedotin and R-CHP Achieve 100% Complete Response ...
Zilovertamab vedotin in the treatment of mantle cell lymphoma | VJHemOnc
(PDF) The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the ...
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy - Assay ...
ASH五分钟丨郭晔教授盘点淋巴瘤新药研究-肿瘤瞭望
（淋巴瘤）抗ROR1抗體藥Zilovertamab vedotin有效？
100%CR! 惊为天人! ROR1靶点的ADC——zilovertamab vedotin治疗弥漫大B细胞淋巴瘤-MedSci.cn
靶向 ROR1 且不伤正常 B 细胞：糖工程抗体 GE-zilovertamab 开启 CLL 免疫治疗新路径 - 知乎
默沙东ADC新药Zilovertamab vedotin：DLBCL一线治疗实现100%完全缓解！_摩熵医药(原药融云)
(Zilovertamab vedotin) - 药物靶点：ROR1 x Tubulin_在研适应症：弥漫性大B细胞淋巴瘤，复发性弥漫性大B ...
Zilovertamab/Ibrutinib Elicits Durable Responses With Favorable ...
【速递】ROR1 ADC治疗1L DLBCL进入3期临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
国内首家！默沙东申报ROR1抗体偶联药物 11月10日，CDE官网显示， 默沙东 靶向ROR1的抗体偶联药物（ADC）zilovertamab ...
默沙东：ROR1 ADC报临床，ROR1靶点展现抗癌潜力 - 知乎
ROR antagonist | ROR inhibitor | ROR agonist | ROR activator
再発・難治性のびまん性大細胞型B細胞リンパ腫に対するzilovertamab vedotinと標準化学療法の併用、安全かつ良好な奏効率を示す ...
(Zilovertamab vedotin)-药物靶点：ROR1 + Tubulin_在研适应症：弥漫性大B细胞淋巴瘤，B细胞恶性肿瘤，复发性 ...
ROR1 mAb (Zilovertamab) - NewEast Biosciences - GTPase, Oncogene and ...
Anti-ROR1 (zilovertamab biosimilar) mAb-ROR1 Biosimilar mAb for ELISA ...
Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 ...
Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating ...
Zilovertamab，anti-ROR1 antibody 抗体 - ChemicalBook
Rare intrascrotal tumors in a tertiary cancer center: A retrospective ...
:%0A%0AZilovertamab%20Vedotin%20+%20R-CHP%20for%20Diffuse%20Large%20B-Cell%20Lymphoma.png?md=1)
.png)
.png)
